NEW YORK, July 1, 2016 /PRNewswire/ --
Market volatility and economic uncertainties are adding more
pressure to firms in the Biotech arena, but opportunities are ever
present in select companies. Take a look at today's featured
equities on Stock-Callers.com and review their recent performances:
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), Idera Pharmaceuticals
Inc. (NASDAQ: IDRA), Threshold Pharmaceuticals Inc. (NASDAQ: THLD),
and Viking Therapeutics Inc. (NASDAQ: VKTX). Click below to receive
your free trade alerts on these stocks and more:
http://stock-callers.com/registration
To access Stock-Callers.com full PDF Research
Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
SNTA Research
Package: http://stock-callers.com/registration/?symbol=SNTA
IDRA Research
Package: http://stock-callers.com/registration/?symbol=IDRA
THLD Research
Package: http://stock-callers.com/registration/?symbol=THLD
VKTX Research
Package: http://stock-callers.com/registration/?symbol=VKTX
============
Lexington, Massachusetts-based
Synta Pharmaceuticals Corp.'s shares saw a decline of 2.98%,
closing Thursday's trading session at $0.26. The stock recorded a trading volume of
386,502 shares. Shares of the Company have advanced 4.08% in the
previous three months. The stock is trading 27.96% below its 50-day
moving average. Additionally, shares of Synta Pharmaceuticals,
which focuses on the research, development, and commercialization
of novel oncology medicines for cancer patients, have a Relative
Strength Index (RSI) of 31.00.
On Thursday, shares in Cambridge,
Massachusetts-based clinical-stage biopharmaceutical
Company, Idera Pharmaceuticals Inc., recorded a trading volume of
597,494 shares. The stock edged 4.08% higher, ending the day at
$1.53. The Company's shares are
trading below their 50-day moving average by 0.87%. Furthermore,
shares of Idera Pharmaceuticals, which focuses on the discovery,
development, and commercialization of therapeutics for oncology and
rare diseases in the U.S., have an RSI of 50.12.
South San Francisco, California
headquartered clinical-stage biotechnology Company, Threshold
Pharmaceuticals Inc.'s stock finished the day 9.55% higher at
$0.64. A total volume of 2.96 million
shares was traded, which was above their three months average
volume of 1.03 million shares. The Company's shares have surged
35.19% in the last one month, 38.13% in the previous three months,
and 32.38% on an YTD basis. The stock is trading above its 50-day
moving average by 48.53%. Additionally, shares of Threshold
Pharmaceuticals, which discovers and develops therapeutic agents
that target tumor cells for the treatment of patients living with
cancer in the U.S., have an RSI of 67.73.
Shares in San Diego, California
headquartered clinical-stage biopharmaceutical Company, Viking
Therapeutics Inc., ended yesterday's session 5.00% higher at
$1.26. The stock recorded a trading
volume of 82,827 shares. The Company's shares are trading 3.65%
below their 50-day moving average. Moreover, shares in Viking
Therapeutics, which focuses on the development of therapies for
metabolic and endocrine disorders, have an RSI of 48.50.
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA